The federal multidistrict litigation (MDL) over Ozempic and other GLP-1 drugs continues to expand, now encompassing claims related to Saxenda but remaining focused on gastrointestinal injuries like gastroparesis, small bowel obstruction, and gallbladder issues
Edit Read Today's E-edition Share This Copyright 2026 Arizona Daily Star, PO Box 26887 Tucson, AZ 85726-6887 Terms of Use | Privacy Policy | Advertising Terms of Use | Do Not Sell My Info | Cookie Preferences Powered by BLOX Content Management System from bloxdigital } summary Notifications Settings Get up-to-the-minute news sent straight to your device
When asked about the results that particularly stood out, Dr Al-Aly highlighted the effect on substance use disorders
Moreover, continuous pharmaceutical innovation and favorable healthcare reimbursement policies are further contributing to market growth across Japan
However, they are indicated for distinct uses and follow different dosage strategies to achieve their therapeutic effects.